Uniqure NV (NASDAQ:QURE) Insider Robert Gut Sells 4,769 Shares

Uniqure NV (NASDAQ:QURE) insider Robert Gut sold 4,769 shares of the stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $47.16, for a total value of $224,906.04. Following the completion of the transaction, the insider now directly owns 35,378 shares in the company, valued at approximately $1,668,426.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of NASDAQ QURE traded down $0.43 during mid-day trading on Friday, reaching $46.99. 5,385 shares of the company’s stock were exchanged, compared to its average volume of 658,771. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -20.08 and a beta of 0.96. The company has a current ratio of 8.07, a quick ratio of 8.07 and a debt-to-equity ratio of 0.51. The business has a fifty day simple moving average of $53.27 and a 200 day simple moving average of $61.97. Uniqure NV has a twelve month low of $21.98 and a twelve month high of $82.49.

Uniqure (NASDAQ:QURE) last released its quarterly earnings results on Monday, July 29th. The biotechnology company reported ($0.83) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.08). The business had revenue of $2.47 million for the quarter, compared to analyst estimates of $1.53 million. Uniqure had a negative return on equity of 61.67% and a negative net margin of 1,232.30%. Equities research analysts predict that Uniqure NV will post -3.22 earnings per share for the current fiscal year.



Several equities analysts have weighed in on the company. Guggenheim lowered Uniqure from a “buy” rating to a “neutral” rating in a research note on Monday, July 29th. Chardan Capital reissued a “buy” rating on shares of Uniqure in a research note on Tuesday, September 3rd. Mizuho assumed coverage on Uniqure in a research note on Thursday, September 12th. They issued a “buy” rating and a $67.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $94.00 target price (up previously from $81.00) on shares of Uniqure in a research note on Monday, July 8th. Finally, Janney Montgomery Scott reissued a “buy” rating on shares of Uniqure in a research note on Tuesday, June 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $77.25.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. Griffin Asset Management Inc. acquired a new stake in shares of Uniqure during the second quarter worth about $39,000. US Bancorp DE raised its position in shares of Uniqure by 275.5% during the second quarter. US Bancorp DE now owns 582 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 427 shares during the period. Botty Investors LLC acquired a new stake in shares of Uniqure during the second quarter worth about $78,000. Rockefeller Capital Management L.P. acquired a new stake in shares of Uniqure during the second quarter worth about $78,000. Finally, Aperio Group LLC acquired a new stake in shares of Uniqure during the second quarter worth about $83,000. 69.89% of the stock is currently owned by institutional investors.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Featured Article: Does the Dogs of the Dow strategy work?

Insider Buying and Selling by Quarter for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.